Remission of disseminated cancer after systemic oncolytic virotherapy - PubMed (original) (raw)
Case Reports
doi: 10.1016/j.mayocp.2014.04.003. Epub 2014 May 14.
Mark J Federspiel 2, Kah-Whye Peng 2, Caili Tong 2, David Dingli 1, William G Morice 3, Val Lowe 4, Michael K O'Connor 4, Robert A Kyle 5, Nelson Leung 6, Francis K Buadi 5, S Vincent Rajkumar 5, Morie A Gertz 5, Martha Q Lacy 5, Angela Dispenzieri 7
Affiliations
- PMID: 24835528
- PMCID: PMC4225126
- DOI: 10.1016/j.mayocp.2014.04.003
Case Reports
Remission of disseminated cancer after systemic oncolytic virotherapy
Stephen J Russell et al. Mayo Clin Proc. 2014 Jul.
Abstract
MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple glucose-avid plasmacytomas were treated by intravenous infusion of 10(11) TCID50 (50% tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy with M protein reduction and resolution of bone marrow plasmacytosis. Further, one patient experienced durable complete remission at all disease sites. Tumor targeting was clearly documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas. Toxicities resolved within the first week after therapy. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated cancer.
Copyright © 2014 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.
Figures
FIGURE 1
Clinical response to systemically administered MV-NIS. A, Serial free light chain (FLC) measurements in patients 1 and 2 as a surrogate of myeloma tumor burden, increasing at myeloma relapse and decreasing after successful therapy. Asterisks indicate the timing of relevant bone marrow (BM) and positron emission tomography—computed tomography (PET-CT) examinations. B, High-sensitivity 8-color plasma cell (PC) flow cytometry performed on pretherapy BM samples from both patients (left panels) shows CD38- and CD138-positive, CD19-negative monoclonal PCs (λ-restricted in patient 1, κ-restricted in patient 2) with hyperdiploid DNA content. In these same studies performed on BM samples obtained 6 weeks after therapy (right panels), the abnormal PCs are not present. C, Alternate coronal PET-CT sections at the level of the left frontal plasmacytoma in patient 1 before and 7 weeks after MV-NIS therapy. Far right panel shows higher magnification of the middle sections, focusing on the plasmacytoma. Note the pretherapy cerebral compression and altered skin contour that normalize after therapy. ASCT = autologous stem cell transplant; DAPI = 4′,6′-diamidino-2-phenylindole; MV = measles virus; UNL = upper normal limit.
FIGURE 2
Intratumoral propagation of systemically administered MV-NIS. A, Serial single-photon emission computed tomography (SPECT)—computed tomography (CT) images from patient 1 at baseline (d-1) and on days 8 (d8) and 15 (d15) after MV-NIS infusion at the level of the left frontal plasmacytoma. Two adjacent transaxial slices from 6 hours after isotope administration are shown for each time point. There is a small area of increased uptake in the plasmacytoma visible in the lower slice on the day 8 scan (circle). This area of increased uptake is more extensive, and visible in both slices (circles), on the day 15 scan. B, Serial SPECT-CT images from patient 2 at baseline and on days 8, 15, and 28 (d28) after MV-NIS infusion at the level of the inguinal region. Compared with the baseline images, there is greatly increased radioiodine uptake in a deep-seated intramuscular plasmacytoma in the right hemipelvis on day 8 after MV-NIS administration, which is diminishing by day 15 and is back to baseline by day 28 (arrows). On the same transaxial slices, there is moderately increased radioiodine uptake in the large left inguinal lymph node on day 8, which again is diminishing by day 15 and back to baseline by day 28 (arrowheads). C, Anteroposterior fluorodeoxyglucose positron emission tomography (PET)—CT image obtained before MV-NIS administration and the corresponding iodine 123 SPECT-CT images obtained 8 days and 28 days after virus administration. All areas of intense radioiodine uptake (aside from the bladder) in the day 8 SPECT-CT scan are seen to correspond to glucose-avid plasmacytomas in the PET-CT image (circles).
Comment in
- Taming measles virus to create an effective cancer therapeutic.
Bell JC. Bell JC. Mayo Clin Proc. 2014 Jul;89(7):863-5. doi: 10.1016/j.mayocp.2014.04.009. Epub 2014 May 14. Mayo Clin Proc. 2014. PMID: 24835529 No abstract available.
Similar articles
- Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.
Dispenzieri A, Tong C, LaPlant B, Lacy MQ, Laumann K, Dingli D, Zhou Y, Federspiel MJ, Gertz MA, Hayman S, Buadi F, O'Connor M, Lowe VJ, Peng KW, Russell SJ. Dispenzieri A, et al. Leukemia. 2017 Dec;31(12):2791-2798. doi: 10.1038/leu.2017.120. Epub 2017 Apr 25. Leukemia. 2017. PMID: 28439108 Free PMC article. Clinical Trial. - Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.
Peng KW, Dogan A, Vrana J, Liu C, Ong HT, Kumar S, Dispenzieri A, Dietz AB, Russell SJ. Peng KW, et al. Am J Hematol. 2009 Jul;84(7):401-7. doi: 10.1002/ajh.21444. Am J Hematol. 2009. PMID: 19507209 Free PMC article. - Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.
Packiriswamy N, Upreti D, Zhou Y, Khan R, Miller A, Diaz RM, Rooney CM, Dispenzieri A, Peng KW, Russell SJ. Packiriswamy N, et al. Leukemia. 2020 Dec;34(12):3310-3322. doi: 10.1038/s41375-020-0828-7. Epub 2020 Apr 23. Leukemia. 2020. PMID: 32327728 Free PMC article. Clinical Trial. - Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.
Msaouel P, Dispenzieri A, Galanis E. Msaouel P, et al. Curr Opin Mol Ther. 2009 Feb;11(1):43-53. Curr Opin Mol Ther. 2009. PMID: 19169959 Free PMC article. Review. - Measles to the Rescue: A Review of Oncolytic Measles Virus.
Aref S, Bailey K, Fielding A. Aref S, et al. Viruses. 2016 Oct 22;8(10):294. doi: 10.3390/v8100294. Viruses. 2016. PMID: 27782084 Free PMC article. Review.
Cited by
- Oncolytic Viral Therapy in Osteosarcoma.
Karadimas T, Huynh TH, Chose C, Zervoudakis G, Clampitt B, Lapp S, Joyce D, Letson GD, Metts J, Binitie O, Mullinax JE, Lazarides A. Karadimas T, et al. Viruses. 2024 Jul 16;16(7):1139. doi: 10.3390/v16071139. Viruses. 2024. PMID: 39066301 Free PMC article. Review. - In Vitro Sensitivity of Neuroendocrine Neoplasms to an Armed Oncolytic Measles Vaccine Virus.
Scheicher NV, Berchtold S, Beil J, Smirnow I, Schenk A, Lauer UM. Scheicher NV, et al. Cancers (Basel). 2024 Jan 23;16(3):488. doi: 10.3390/cancers16030488. Cancers (Basel). 2024. PMID: 38339240 Free PMC article. - Radiovirotherapy at twenty.
Dingli D. Dingli D. Mol Ther Oncolytics. 2023 May 26;29:127-128. doi: 10.1016/j.omto.2023.05.003. eCollection 2023 Jun 15. Mol Ther Oncolytics. 2023. PMID: 37260766 Free PMC article. No abstract available. - Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells.
Holmes M, Scott GB, Heaton S, Barr T, Askar B, Müller LME, Jennings VA, Ralph C, Burton C, Melcher A, Hillmen P, Parrish C, Errington-Mais F. Holmes M, et al. Mol Ther Oncolytics. 2023 Mar 24;29:17-29. doi: 10.1016/j.omto.2023.03.002. eCollection 2023 Jun 15. Mol Ther Oncolytics. 2023. PMID: 37077714 Free PMC article. - Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment.
Ghasemi Darestani N, Gilmanova AI, Al-Gazally ME, Zekiy AO, Ansari MJ, Zabibah RS, Jawad MA, Al-Shalah SAJ, Rizaev JA, Alnassar YS, Mohammed NM, Mustafa YF, Darvishi M, Akhavan-Sigari R. Ghasemi Darestani N, et al. Cell Commun Signal. 2023 Feb 24;21(1):43. doi: 10.1186/s12964-022-01012-0. Cell Commun Signal. 2023. PMID: 36829187 Free PMC article. Review.
References
- Tong AW, Senzer N, Cerullo V, Templeton NS, Hemminki A, Nemunaitis J. Oncolytic viruses for induction of anti-tumor immunity. Curr Pharm Biotechnol. 2012;13(9):1750–1760. - PubMed
- Kyle RA, Rajkumar SV. An overview of the progress in the treatment of multiple myeloma. Exp Rev Hematol. 2014;7(1):5–7. - PubMed
- Dingli D, Peng KW, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood. 2004;103(5):1641–1646. - PubMed
Publication types
MeSH terms
Grants and funding
- R01 CA168719/CA/NCI NIH HHS/United States
- R01CA125614/CA/NCI NIH HHS/United States
- P30 CA015083/CA/NCI NIH HHS/United States
- R01CA168719/CA/NCI NIH HHS/United States
- R01 CA125614/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical